The ArteraAI prostate test is claimed to be the first diagnostic tool capable of predicting therapy benefits and projecting long-term outcomes for patients with localised prostate cancer. Credit: Korawat photo shoot / Shutterstock.

Multimodal artificial intelligence (MMAI)-based cancer diagnostics Artera has received a California laboratory licence from the California Department of Public Health (CDPH) to offer its ArteraAI prostate test in the US state’s healthcare market.

The test provides clinicians and patients with advanced insights to tailor cancer treatment strategies effectively.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The company’s MMAI platform leverages AI to analyse haematoxylin and eosin (H&E)-stained pathology slides, integrating digitised images with patient clinical data to deliver customised prognostic information.

Artera co-founder and CEO Andre Esteva said: “Receiving the California lab license is a significant milestone for Artera, allowing us to serve more patients and clinicians across the US.

“Prostate cancer is one of the most common cancers in American men, and the American Cancer Society estimates more than 26,000 men will be diagnosed with prostate cancer in California alone. Our goal is to provide easy and convenient access to AI-powered precision medicine, providing individuals with better insights and clarity in their treatment decisions.”

See Also:

The ArteraAI prostate test is claimed as the first diagnostic tool capable of predicting therapy benefits and projecting long-term outcomes for patients with localised prostate cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

University of California professor of Urology Peter Carroll said: “Artera’s predictive biomarker recognised in national guidelines for localised prostate cancer has the potential to significantly empower treatment decisions, including patients considering androgen deprivation therapy (ADT) in combination with radiation. Both clinicians and patients deserve access to innovative, extensively validated technologies like this to ensure the highest level of personalised and optimal care.”

This development closely follows the College of American Pathologists (CAP) accreditation awarded to Artera in August.